Tandem Diabetes Care Inc

TNDM: XNAS (USA)
View Stock Summary
Morningstar Rating for StocksFair ValueEconomic MoatCapital Allocation
<n@LOCK|TDLOCK|Bf@l>t

Tandem Earnings: Solid Third-Quarter Performance Is Backdrop for Major Management Change

Tandem Diabetes posted third-quarter results that included revenue growth of 14% in constant currency, and gross margin that improved by 270 basis points year over year. International sales growth of 27% was particularly strong.

Sponsor Center